Clinical Trial Update: Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating [18F]APN-1607 PET uptake in Alzheimer's disease patients versus healthy subjects; status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment Due to Alzheimer Disease

Drugs mentioned

• [18F]APN-1607 (APN-1607)

Snippet

Sponsor: APRINOIA Therapeutics, LLC | Conditions: Alzheimer's Disease, Mild Cognitive Impairment Due to Alzheimer's Disease | Phase 2 | Status: UNKNOWN